Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

Study results report no benefit from use of sunitinib, sorafenib among patients with kidney cancer

Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence, the ECOG-ACRIN Cancer Research Group announced.

24 Feb 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

A study led by researchers at the Institute for Molecular Medicine Finland FIMM and Faculty of Medicine, University of Helsinki and the Helsinki University Central Hospital Comprehensive Cancer Center, in close collaboration with researchers at Pfizer, has identified a previously unrecognized action of Pfizer's axitinib as a potent inhibitor of the dominant mutation that confers drug resistance to all well tolerated treatments in patients with certain types of leukemia.

10 Feb 2015

Close, active monitoring of small renal tumors linked to low rates of death

In patients likely to have surgery, close, active monitoring of small renal tumors confined to the kidneys is associated with low rates of tumor growth or death, according to a study by a researcher at the Icahn School of Medicine at Mount Sinai published in the September issue of The Journal of Urology.

22 Jan 2015

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Mirati Therapeutics, Inc. today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD265 in selected patients exhibiting genetic alterations of MET or Axl.

23 Dec 2014

CDK activity predicts RCC recurrence

The specific activity of cyclin-dependent kinase 1 and CDK2 as well as a risk score based on the activity of these enzymes can predict recurrence in patients with renal cell carcinoma, study findings indicate.

19 Dec 2014

Long-term axitinib in RCC effective with ‘controllable’ toxicities

Axitinib treatment is effective in the long-term in Japanese patients with metastatic renal cell carcinoma and has manageable toxicity, a phase II study suggests.

19 Dec 2014

Single biopsy site may reveal all lung adenocarcinoma genetic mutations

Genetic sequencing of a single tumour site sample may be adequate for identifying cancer gene mutations in patients with lung andenocarcinoma, research published in Science suggests.

18 Dec 2014

Metastatic RCC patients may benefit from sequential TKI strategy

For patients with metastatic renal cell carcinoma, sequential tyrosine kinase inhibitor therapy may be better option than changing to a mammalian target of rapamycin inhibitor, research suggests.

17 Dec 2014

RCC renal function independent of axitinib-induced proteinuria

Treatment with the vascular endothelial growth factor receptor inhibitor axitinib does not adversely affect renal function in patients with metastatic renal cell carcinoma even in the presence of proteinuria, a Japanese study indicates.

17 Dec 2014

Cimetidine drug could be one of many common over-the-counter medicines to treat cancer

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want to know why this research isn't more widely used.

27 Nov 2014

Research: HD-IL2 can be effective in mRCC patients pre-treated with VEGF-targeted agents

High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.

24 Nov 2014

Statin use linked to improved RCC surgery outcomes

Statin use at the time of surgery is associated with improved overall survival and disease-specific survival in patients with renal cell carcinoma of any stage, US researchers report.

18 Nov 2014

Nonlinear correlation between axitinib dose, dBP increase

A pharmacokinetic–pharmacodynamic model shows that diastolic blood pressure rises with increasing doses of axitinib in patients with metastatic renal cell carcinoma, US researchers report, although this relationship is not linear.

18 Nov 2014

Sarcomatoid differentiation levels predict poor RCC survival

Research shows that the degree of sarcomatoid differentiation in patients with grade 4 renal cell carcinoma is not only associated with poor survival, but can also serve as an independent prognostic factor in these patients.

14 Nov 2014

Toxicity profiles for everolimus, temsirolimus differ in advanced RCC

Non-infectious pneumonitis and stomatitis occur more frequently in patients with advanced renal cell carcinoma treated with everolimus than temsirolimus, whereas temsirolimus is associated with a higher incidence of fatigue, rash and asthenia, a retrospective study reports.

13 Nov 2014